Pfizer HQ

Pfizer delay, alleged price gouging earns wrath of British watchdog

New York AG Eric Schneiderman

New York AG sues insurer over restrictive hep C coverage


Sanofi's Dengvaxia gets a boost from WHO recommendation


Shire building $400M biologics plant, adding 400 jobs in Ireland

Shire, which operates out of the U.S. but has its domicile in Ireland for tax reasons, will build its first manufacturing facility in its adopted country.

Valeant's headquarters in New Jersey

Valeant looks at what it might sell to raise cash

Valeant has called in investment banks to help it decide which products it might quickly turn into cash if it decides to sell some to pay down its $30 billion…

Allergan CEO Brent Saunders

Allergan CEO, Treasury secretary spar over death of 'Pfizergan' deal

Allergan CEO Brent Saunders has said tax rule changes appeared unfairly targeted toward his company's proposed merger with Pfizer. Not so, Treasury head…

stop sign

Orexigen puts Contrave at risk by stopping yet another heart study

Orexigen lost its Contrave marketing partner Takeda last month. Now, the drugmaker has terminated its second try at an FDA-mandated heart safety study, putting…

Keytruda Opdivo

Merck and Bristol-Myers, locked in head-to-head competition in lung cancer and melanoma, step closer to new indications where they won't lock horns.


Will new drug spending figures increase pressure on pharma?

The annual report on how much the U.S. pays for meds is out--and it will likely serve to further anger those who believe pharma is hiking its prices.

Kathleen Uhl

FDA speeds ahead with new generic approvals in 2015: Report

Regulators signed off on more than 700 generic drugs last year--the highest figure to date, according to the FDA’s first generics annual report, which the…

laptop against white background

As promised, we bring you the new and improved FiercePharma

Many of you saw the new FierceBiotech website launch earlier this week and now I am pleased to bring you the newly redesigned FiercePharma.  Our new website …

Januvia box

Merck's DPP-4 newcomer Marizev trails Januvia in safety: Report

Merck wants its new weekly diabetes treatment, Marizev, to build on the success of its blockbuster DPP-4 inhibitor Januvia. But at least when it comes to…

Horizon has reworked its forecast.

Horizon reworks financial forecast; investors not happy

There is more uncertainty on the horizon for investors in Horizon. Last month, it was the disclosure of a Department of Justice (DOJ) probe into pricing. Today…